Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

被引：0
|
作者：
Dalal, Rahul S. [1 ]
Clarke, Lindsay M. [1 ]
Carlin, Alex [1 ]
Cabral, Heidy [1 ]
Allegretti, Jessica R. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
来源：
INFLAMMATORY BOWEL DISEASES | 2024年
关键词：
ulcerative colitis; inflammatory bowel disease; biologics; bio-na & iuml; ve; INFLAMMATORY-BOWEL-DISEASE;
D O I：
10.1093/ibd/izae215
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-na & iuml;ve patients with ulcerative proctitis.
引用
收藏
页码：1174 / 1177
页数：4
相关论文
共 50 条
  • [31] Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study
    Attauabi, Mohamed
    Vind, Ida
    Pedersen, Gitte
    Bendtsen, Flemming
    Seidelin, Jakob Benedict
    Burisch, Johan
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E709 - E718
  • [32] Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study
    Attauabi, Mohamed
    Vind, Ida
    Pedersen, Gitte
    Bendtsen, Flemming
    Seidelin, Jakob Benedict
    Burisch, Johan
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E709 - E718
  • [33] Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
    Ulf Helwig
    Michael Mross
    Stefan Schubert
    Heinz Hartmann
    Alina Brandes
    Dara Stein
    Christian Kempf
    Jana Knop
    Sarah Campbell-Hill
    Robert Ehehalt
    BMC Gastroenterology, 20
  • [34] Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis
    Straatmijer, Tessa
    van Gennep, Sara
    Duijvestein, Marjolijn
    Ponsioen, Cyriel I. J.
    Gecse, Krisztina B.
    D'Haens, Geert R.
    Lowenberg, Mark
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (10) : 1288 - 1297
  • [35] Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice
    Iida, Takayuki
    Ikeya, Kentaro
    Kato, Masaichi
    Abe, Jinro
    Yamamoto, Masayoshi
    Watanabe, Fumitoshi
    Sugimoto, Ken
    Hanai, Hiroyuki
    DIGESTION, 2017, 96 (02) : 119 - 126
  • [36] Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice
    Sugimoto, Ken
    Ikeya, Kentaro
    Kato, Masaichi
    Matsuura, Ai
    Watanabe, Fumitoshi
    Takano, Ryosuke
    Tamura, Satoshi
    Tani, Shinya
    Osawa, Satoshi
    Hanai, Hiroyuki
    DIGESTIVE DISEASES, 2019, 37 (01) : 11 - 20
  • [37] Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment
    Ylisaukko-Oja, Tero
    af Bjorkesten, Clas-Goran
    Eberl, Anja
    Nuutinen, Heikki
    Jussila, Airi
    Molander, Pauliina
    Koskela, Ritva
    Blomster, Timo
    Pajala, Markku
    Ilus, Tuire
    Haiko, Paula
    Kovac, Bianca
    Silvola, Saija
    Smith, Sarah
    Jokelainen, Jari
    Sipponen, Taina
    HELIYON, 2024, 10 (12)
  • [38] Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
    Chaparro, Maria
    Acosta, Diana
    Rodriguez, Cristina
    Mesonero, Francisco
    Vicuna, Miren
    Barreiro-de Acosta, Manuel
    Fernandez-Clotet, Agnes
    Martinez, Alvaro Hernandez
    Arroyo, Maite
    Vera, Isabel
    Ruiz-Cerulla, Alexandra
    Sicilia, Beatriz
    Tapia, M. Jose Cabello
    Villafranca, Carmen Munoz
    Castro-Poceiro, Jesus
    Cadilla, Jesus Martinez
    Sierra-Ausin, Monica
    Moron, Juan Maria Vazquez
    Lidon, Raquel Vicente
    Bermejo, Fernando
    Royo, Vanesa
    Calafat, Margalida
    Gonzalez-Munoza, Carlos
    Carnerero, Eduardo Leo
    Marcos, Noemi Mancenido
    Torrealba, Leyanira
    Alonso-Galan, Horacio
    Benitez, Jose Manuel
    Nieto, Yolanda Ber
    Palomares, M. Teresa Diz-Lois
    Garcia, Maria Jose
    Munoz, Jose Fernando
    Gonzalez, Edisa Maria Armesto
    Calvet, Xavier
    Hernandez-Camba, Alejandro
    Dominguez, Rosa Eva Madrigal
    Menchen, Luis
    Calle, Jose Lazaro Perez
    Piqueras, Marta
    Sadornil, Carmen Duenas
    Botella, Belen
    Martinez-Perez, Teresa de Jesus
    Ramos, Laura
    Rodriguez-Grau, Maria Carmen
    San Miguel, Elena
    Forcelledo, Jose Luis Fernandez
    Salazar, Paola Maria Fradejas
    Garcia-Sepulcre, Marife
    Gutierrez, Ana
    Llao, Jordina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (07) : 1237 - 1247
  • [39] Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study
    Takagi, Yasuhiro
    Sato, Toshiyuki
    Nishiguchi, Takanori
    Nogami, Akira
    Igeta, Masataka
    Yagi, Soichi
    Ikenouchi, Maiko
    Kawai, Mikio
    Kamikozuru, Koji
    Yokoyama, Yoko
    Tomita, Toshihiko
    Fukui, Hirokazu
    Fukata, Masayuki
    Kobayashi, Taku
    Shinzaki, Shinichiro
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025,
  • [40] Real-World Data on the Effectiveness and Safety of Filgotinib for Ulcerative Colitis in Japanese Patients: A Single-Center Experience
    Toba, Takahito
    Karashima, Ryo
    Fujii, Kodai
    Inoue, Keiichi
    Inoue, Nanako
    Ogawa, Yurie
    Hojo, Aya
    Fujimoto, Ai
    Matsuda, Takahisa
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
12345